Previous 10 | Next 10 |
HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA in...
Gene therapy-focused biotechnology company Benitec Biopharma ( NASDAQ: BNTC ) closed an ~$17.9M underwritten public offering of 29.81M shares and accompanying warrants to purchase up to 29.81M shares. Each share was sold together with one warrant at a combined offering...
HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA i...
Benitec Biopharma ( NASDAQ: BNTC ) has priced its underwritten public offering of 29,809,471 shares of its common stock and accompanying warrants to purchase up to 29,809,471 shares of common stock for an expected gross proceeds to be approximately $17.9M. Each share of co...
HAYWARD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA i...
Benitec press release ( NASDAQ: BNTC ): FY GAAP EPS of -$2.23. Revenue of $0.07M (+16.7% Y/Y). For further details see: Benitec GAAP EPS of -$2.23, revenue of $0.07M
HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA i...
Renalytix ( RNLX ) -28% on Q3 earnings release . Angion Biomedica ( ANGN ) -27% after it discontinued phase 2 trial of ANG-3070 in patients with kidney disease . Exicure ( XCUR ) -23% as it implements reverse-stock-split to get back Nasdaq com...
Agile Therapeutics ( AGRX ) -16% . Bed Bath & Beyond ( BBBY ) -13% on Q1 earnings release . Barnes & Noble Education ( BNED ) -15% on Q4 earnings release . Himax Technologies ( HIMX ) -12% . AeroVironment ( AVAV ) -...
Cognyte Software (CGNT) -23% on Q1 earnings release. Acutus Medical (AFIB) -9%. Benitec Biopharma (BNTC) -9%. Fujian Blue Hat Interactive Entertainment Technology (BHAT) -8%. ToughBuilt Industries (TBLT) -6%. NeuroSense Therapeutics (NRSN) -6%. For further details see: Cognyte...
News, Short Squeeze, Breakout and More Instantly...
Benitec Biopharma Limited Company Name:
BNTC Stock Symbol:
NASDAQ Market:
Benitec Biopharma Limited Website:
2024-07-16 20:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose of gene therapy BB-301 as ...
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace ...